Updates and Insights on HER2 in Breast Cancer in Sohag Governorate (NCT07758127) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Updates and Insights on HER2 in Breast Cancer in Sohag Governorate
Egypt100 participantsStarted 2026-09
Plain-language summary
* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.
* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes
* To access interobserval agreement in HER2 score interpretation
Who can participate
Age range
26 Years – 85 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Breast cancer cases diagnosed during 2025 and 2026.
* Cases with available HER2 immunohistochemical results.
* Cases with sufficient tissue material for evaluation.
* Cases with complete clinical and follow-up data.
* Cases that were accessible for pathologic review
Exclusion Criteria:
* Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.
* Cases with incomplete clinical information.
* Cases lacking adequate immunohistochemical assessment.
* Cases outside the study period
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
HER2 status in breast cancer
Timeframe: 2025/2026
Trial details
NCT IDNCT07758127
SponsorSohag University
Sponsor typeOTHER
Study typeOBSERVATIONAL
Primary completion2027-09
Contact for this trial
Dr. Fatma El-Zahraa Prof. Dr. Fatma El-Zahraa Salah El-Deen Safe El-Deen, Professor of Pathology